Subsequent studies using EGFR and BRAF inhibition with vemurafenib and cetuximab in Class 1 BRAF-mutant CRC revealed mild improvements in ORR, but still did achieve the clinical efficacy of single-agent BRAF inhibition in other BRAF-mutated cancer types [15,16]. This evidence concerns the gene BRAF and cancer.